Safety and Efficacy of 20 Cycles of [<sup>177</sup>Lu]Lu-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer
Current randomized controlled data ([1][1] , [2][2]) demonstrate the safety and efficacy of 6 cycles of [177Lu]Lu-PSMA-617 therapy in men with metastatic castration-resistant prostate cancer. In our first phase 2 trial ([3][3]), 15 of 30 patients received additional cycles; 11 (73%) had a subsequent
Authors
- Kerry Jewell (ORCID: https://orcid.org/0000-0003-1426-0113)
- Elizabeth Medhurst
- James P Buteau (ORCID: https://orcid.org/0000-0001-5693-2913)
- Michael S. Hofman (ORCID: https://orcid.org/0000-0001-8622-159X)
- Shahneen Kaur Sandhu (ORCID: https://orcid.org/0000-0002-8660-4475)
- Arun Azad (ORCID: https://orcid.org/0000-0001-7350-5622)
- Edmond M. Kwan (ORCID: https://orcid.org/0000-0002-7053-680X)
Institutions
- The University of Melbourne (AU)
- Peter MacCallum Cancer Centre (AU)
- Monash University (AU)
Publication Details
- Journal
- Journal of Nuclear Medicine
- Published
- 2025-03-13
- DOI
- https://doi.org/10.2967/jnumed.124.269447
- Citations
- 1
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 1.52